ZURICH, March 6 (Reuters) - Swiss drugmaker Roche still hopes to succeed with its $5.7 billion hostile cash bid for U.S. gene decoder Illumina, but sees other alternatives if the takeover fails.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results